Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CardioComm Solutions Inc V.EKG

Alternate Symbol(s):  EKGGF

CardioComm Solutions, Inc. is a global medical provider of consumer heart monitoring and medical electrocardiogram (ECG) software solutions. The Company’s technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. It develops advanced software, hardware and core laboratory reading services related to ECG and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. Its Global ECG Management Solutions (GEMS) and GlobalCardio (Cloud based GEMS) products are licensed worldwide to hospitals, ECG commercial reading services and physicians. The Company is also engaged in manufacturing, marketing, and sales of personal ECG monitors direct to consumers. The products are marketed under the HeartCheck brand. It has developed compatibility of the HeartCheck device to its GEMS and GlobalCardio based software to enable use of the device for remote ECG/arrhythmia monitoring services.


TSXV:EKG - Post by User

Bullboard Posts
Post by habstraderson Feb 22, 2019 1:37pm
92 Views
Post# 29400884

FDA 510(k) review is due tomorrow.

FDA 510(k) review is due tomorrow. The Company has now provided the FDA a restatement of their response for additional information as of January 23, 2019, which the FDA has confirmed received. The FDA will now have 31 days to complete the 510(k) review of CardioComm's restated submission.

January 23 + 31 days = February 24 (saturday) that's why the company is halted today. I don't expect any bad news :) 

Been a shareholder in this company for almost 7 years, always believe in the potential of this company and their products. This is an exciting moment for all shareholders. It will be an atomic bomb .
Bullboard Posts